Aclaris Therapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $517.87 million
- Book Value:
- Revenue TTM:
- $29.75 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Aclaris Therapeutics Inc had its IPO on 2015-10-07 under the ticker symbol ACRS.
The company operates in the Healthcare sector and Diagnostics & Research industry. Aclaris Therapeutics Inc has a staff strength of 100 employees.
Shares of Aclaris Therapeutics Inc opened at $8.11 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $7.72 - $8.42, and closed at $7.89.
This is a -2.83% slip from the previous day's closing price.
A total volume of 958,400 shares were traded at the close of the day’s session.
In the last one week, shares of Aclaris Therapeutics Inc have increased by +3%.
Aclaris Therapeutics Inc's Key Ratios
Aclaris Therapeutics Inc has a market cap of $517.87 million, indicating a price to book ratio of 4.9048 and a price to sales ratio of 43.6278.
In the last 12-months Aclaris Therapeutics Inc’s revenue was $29.75 million with a gross profit of $-60021000 and an EBITDA of $-84357000. The EBITDA ratio measures Aclaris Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Aclaris Therapeutics Inc’s operating margin was -286.21% while its return on assets stood at -21.04% with a return of equity of -44.01%.
In Q4, Aclaris Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 416.5%.
Aclaris Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.77 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.13. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aclaris Therapeutics Inc’s profitability.
Aclaris Therapeutics Inc stock is trading at a EV to sales ratio of 35.3605 and a EV to EBITDA ratio of -10.004. Its price to sales ratio in the trailing 12-months stood at 43.6278.
Aclaris Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $254.60 million
- Total Liabilities
- $21.94 million
- Operating Cash Flow
- $2.70 million
- Capital Expenditure
- Dividend Payout Ratio
Aclaris Therapeutics Inc ended 2023 with $254.60 million in total assets and $0 in total liabilities. Its intangible assets were valued at $254.60 million while shareholder equity stood at $197.62 million.
Aclaris Therapeutics Inc ended 2023 with $367000.00 in deferred long-term liabilities, $21.94 million in other current liabilities, 66688647000.00 in common stock, $-86908000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $45.28 million and cash and short-term investments were $217.57 million. The company’s total short-term debt was $684,000 while long-term debt stood at $0.
Aclaris Therapeutics Inc’s total current assets stands at $229.81 million while long-term investments were $12.24 million and short-term investments were $172.29 million. Its net receivables were $484000.00 compared to accounts payable of $10.35 million and inventory worth $0.
In 2023, Aclaris Therapeutics Inc's operating cash flow was $2.70 million while its capital expenditure stood at $105000.
Comparatively, Aclaris Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Aclaris Therapeutics Inc stock is currently trading at $7.89 per share. It touched a 52-week high of $18.958 and a 52-week low of $18.958. Analysts tracking the stock have a 12-month average target price of $32.88.
Its 50-day moving average was $13.51 and 200-day moving average was $15.18 The short ratio stood at 3.73 indicating a short percent outstanding of 0%.
Around 314.7% of the company’s stock are held by insiders while 10026.5% are held by institutions.
Frequently Asked Questions About Aclaris Therapeutics Inc
Similar Industry Stocks (Diagnostics & Research)
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.